Summer Selection: Tobacco, Pharma Or Retail Stocks?

GlaxoSmithKline plc (LON:GSK), British American Tobacco plc (LON:BATS) and Next plc (LON:NXT) are under the spotlight.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The summer lull is upon us, so the obvious question is: will investors bet on more defensive sectors this summer?

In short, it goes down to fundamentals, rather than seasonality.

Retail, Pharma, Or Tobacco?

Consider GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), British American Tobacco (LSE: BATS) and Next (LSE: NXT).

Shares of Glaxo and BAT — two of the largest players in the tobacco and pharmaceutical industries, respectively — have been outperformed by Next’s since mid-June. In fact, the shares of the clothing and home products retailer have outperformed those of BAT by almost three percentage points, and those of Glaxo by about seven percentage points at the time of writing. 

Track record, long-term trends and prospects of growth also suggest that: Glaxo is the laggard, and could be bought on the cheap right now; BAT is a relatively stable business whose stock looks undervalued; and Next may continue to outperform the other two, but only if its growth trajectory beats expectations.

NextNext: A Bit Pricey

Next stock has been looking for direction since the end of the first quarter. It is now close to its record highs.

It’s the riskiest bet, but could certainly yield market-beating returns. Next is a solid retailer. Its fundamentals are strong, and its stock is less volatile than those of smaller high-street competitors. Its valuation, however, is demanding.

With a market cap plus net debt (Enterprise Value, or EV) of 11 times forward earnings, before interest, tax, depreciation and amortisation (EBITDA), Next is not a bargain. It needs growth, and lots of it, to continue its formidable run on the stock market.

Efficiency will likely support growth in earnings per share (EPS); market consensus estimates are for EPS growth at about 10% annually  in the next couple of years. Such a growth rate is well below Next’s trailing performance, which points to possible downside for shareholders. It’s a close call, but I would hold Next as part of a diversified portfolio. 

GlaxoSmithKlineGlaxo: A Bargain?

The ongoing bribery saga in China weighs on Glaxo’s valuation, but I’d argue that bad news is already fully priced into Glaxo stock.

At about 11 times forward EV/EBITDA, Glaxo bears the hallmarks of a company whose valuation has been battered well beyond fair value, particularly if its trading multiples are compared to those of other pharmaceutical companies in the UK. Shire stock trades at 18 times forward EV/EBITDA, while AstraZeneca stock is valued at 12 times forward EV/EBITDA.

Several aspects of these three businesses are different, so a straight comparison based on their trading multiples is by no means the only tool a savvy investors should use. It appears clear, however, that the equity values of Shire and AstraZeneca have rallied on the back of takeover talk, rather than in the wake of significant improvements on the business side. The latest £30bn offer from AbbVie, which was announced on Tuesday,  is particularly unappealing for Shire shareholders. 

For its part, with a market cap of £76bn, Glaxo is much bigger than AstraZeneca (£56bn) and Shire (£27bn), and is an unlikely takeover target. If rumours swirling around AstraZeneca and Shire evaporate, Glaxo stock will outperform its smaller rivals, in my view.

british american tobacco / imperial tobaccoBAT: More Upside Than Downside

BAT stock is up 11% this year. Its trading multiples suggest upside could be between 5% and 10% to the end of 2014.

BAT’s long-term prospects, according to market consensus estimates, suggest limited growth for revenue, although EPS growth is forecast in the region of 8% annually to the end of 2016. With a 4% dividend yield, BAT is a less risky bet in the current environment — although I think Glaxo will really surprise investors.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alessandro doesn't own shares in any of the companies mentioned. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »